Clovis Oncology Inc (NASDAQ:CLVS) Q4 2017 Institutional Investor Sentiment Steady

April 16, 2018 - By Vivian Park

Clovis Oncology, Inc. (NASDAQ:CLVS) Logo

Sentiment for Clovis Oncology Inc (NASDAQ:CLVS)

Clovis Oncology Inc (NASDAQ:CLVS) institutional sentiment decreased to 1.05 in Q4 2017. Its down -0.39, from 1.44 in 2017Q3. The ratio has dropped, as 109 institutional investors increased or opened new positions, while 104 cut down and sold positions in Clovis Oncology Inc. The institutional investors in our partner’s database now own: 49.09 million shares, up from 47.46 million shares in 2017Q3. Also, the number of institutional investors holding Clovis Oncology Inc in their top 10 positions decreased from 4 to 3 for a decrease of 1. Sold All: 35 Reduced: 69 Increased: 78 New Position: 31.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $2.78 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

The stock decreased 9.27% or $5.62 during the last trading session, reaching $55.02. About 930,196 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since April 16, 2017 and is downtrending. It has underperformed by 32.98% the S&P500.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on May, 2. They expect $-1.34 EPS, down 0.75 % or $0.01 from last year’s $-1.33 per share. After $-1.27 actual EPS reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 5.51 % negative EPS growth.

Palo Alto Investors Llc holds 9.97% of its portfolio in Clovis Oncology, Inc. for 3.40 million shares. Venbio Select Advisor Llc owns 1.10 million shares or 4.86% of their US portfolio. Moreover, Redmile Group Llc has 3.91% invested in the company for 1.32 million shares. The New York-based Iguana Healthcare Management Llc has invested 2.66% in the stock. Healthcor Management L.P., a New York-based fund reported 973,840 shares.#img1#

Since January 1, 0001, it had 0 insider purchases, and 7 insider sales for $1.64 million activity.

Clovis Oncology, Inc. (NASDAQ:CLVS) Ratings Coverage

Ratings analysis reveals 89% of Clovis Oncology’s analysts are positive. Out of 9 Wall Street analysts rating Clovis Oncology, 8 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $7300 while the high is $110. The stock’s average target of $86.63 is 57.45% above today’s ($55.02) share price. CLVS was included in 14 notes of analysts from October 23, 2017. Barclays Capital maintained the stock with “Overweight” rating in Tuesday, February 27 report. SunTrust maintained the shares of CLVS in report on Friday, April 6 with “Buy” rating. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Outperform” rating by RBC Capital Markets on Thursday, February 22. The rating was upgraded by Evercore on Thursday, February 22 to “Outperform”. The firm has “Overweight” rating by Morgan Stanley given on Thursday, November 2. Oppenheimer initiated the shares of CLVS in report on Friday, March 23 with “Hold” rating. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Buy” rating by Leerink Swann on Wednesday, November 15. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, February 27 report. The stock has “Buy” rating by Leerink Swann on Monday, February 5. Credit Suisse maintained the stock with “Buy” rating in Thursday, January 18 report.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.